Results 271 to 280 of about 24,125,302 (404)

Real-world pharmacovigilance reports of hepatitis A inactivated and hepatitis B (recombinant) vaccine: insights from disproportionality analysis of the vaccine adverse event reporting system. [PDF]

Front Cell Infect Microbiol
Zhou Y, Wang Y, Feng Y, Zhang H, Sun T, Xu J.   +5 more
europepmc   +1 more source

Serological Studies on Hepatitis

, 1959
Toshio Itano
openalex   +2 more sources

Harnessing Viral Proteases for Cellular and Molecular Engineering

Chemistry–Methods, EarlyView.
Engineered viral proteases (VIPs) provide programmable control of protein function with high specificity and low toxicity. Integrated with chemogenetic and optogenetic modules, these VIP systems enable logic gate manipulation for targeted regulation of cell signaling, gene expression, protein secretion, and degradation, thereby offering versatile ...
Mingguang Cui, Tien‐Hung Lan, Yubin Zhou   +2 more
wiley   +1 more source

Non coverage of Hepatitis B immunization among children and its predictors in northeastern states of India: A multiscale geographically weighted regression analysis. [PDF]

J Family Med Prim Care
Gupta S, Singh KJ, Kumar K, Khan MA, Gupta R, Sharma S.   +5 more
europepmc   +1 more source

Evaluation of Potential Effects of CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Fruquintinib in Healthy Subjects

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Cytochrome P450 (CYP) 3A plays a significant role in fruquintinib metabolism in vitro. This 2‐part, 2‐period fixed‐sequence study investigated the impact of CYP3A inhibition (itraconazole) and CYP3A induction (rifampin) on the pharmacokinetics (PK) of fruquintinib and M11, its main metabolite.
Martha Gonzalez, Zhao Yang, William R Schelman, Xiaofei Zhou, Neeraj Gupta, Caly Chien   +5 more
wiley   +1 more source

Construction and validation of a nomogram prediction model for antiviral efficacy based on clinical characteristics and intestinal microflora distribution in patients with chronic hepatitis B. [PDF]

Front Med (Lausanne)
Wu H, Yue M, Wang T, Wei X, Wang Y, Si C.   +5 more
europepmc   +1 more source

Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus

Hepatology, 2015
Aasld Idsa Hcv Guidance Panel
semanticscholar   +1 more source

Effect of Mild to Moderate Hepatic Impairment on Valemetostat Pharmacokinetics: An Open‐Label, Phase I Study

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Valemetostat tosylate (valemetostat) is a dual inhibitor of enhancer of zeste homolog (EZH) 2 and EZH1, approved in Japan for the treatment of relapsed/refractory peripheral T‐cell lymphoma and adult T‐cell leukemia/lymphoma. This Phase I, open‐label study evaluated the pharmacokinetics and safety of a single 50‐mg oral dose of valemetostat in
Masaya Tachibana, Thuy Vu Craveiro, Thomas C. Marbury, Samuel Oberstein, George J. Atiee, Ben Tao, Takako Shimizu, Yvonne Lau, Malaz A. Abutarif   +8 more
wiley   +1 more source

Unhealthy Behaviours and All-Cause Mortality Among People With Chronic Hepatitis B, With and Without Hepatitis Delta (ANRS CO22 HEPATHER). [PDF]

J Viral Hepat
Ramier C, Carrat F, Beo VD, Parlati L, Lotto M, Marcellin F, Protopopescu C, Carrieri P, Bourliere M, ANRS/AFEF HEPATHER study group.   +9 more
europepmc   +1 more source

INFECTIVE HEPATITIS AND CIRRHOSIS OF THE LIVER¹

, 1951
P. B. Fernando, R. S. THANABALASUNDERAM
openalex   +1 more source